• Educational resources
  • Events
  • Expert Panel
  • Learning Hub
    Learning Hub
    • EoE Learning Hub
    • Bullous Pemphigoid Learning Hub
    • Chronic Spontaneous Urticaria Learning Hub
    • COPD Learning Hub
    • Rhinology Learning Hub
    • Type 2 Asthma Learning Hub
    • Prurigo Nodularis Learning Hub
    • Atopic Dermatitis Learning Hub
No matches
  • Cookie policy
  • Privacy policy
  • About us
  • Join ADVENT
  • Contact us

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: The NetherlandsChange country/region

Educational Resources

Categories
Dermatology: 
  • Atopic dermatitis
  • Bullous pemphigoid
  • Chronic pruritus of unknown origin
  • Chronic spontaneous urticaria
  • Prurigo nodularis
Gastroenterology: 
  • Eosinophilic esophagitis
Pulmonology: 
  • Asthma
  • Chronic obstructive pulmonary disease
  • IL-33
Rhinology: 
  • Chronic rhinosinusitis with nasal polyps
Filters
Topic: 
  • Burden of disease
  • Pathophysiology
  • Guidelines and recommendations
  • Clinical management
  • Co-existing type 2 inflammatory diseases
Format: 
  • Expert Video
  • Podcast
  • Slide presentation
  • Infographic
  • Video animation
  • Interactivity
Length: 
  • Short (<5 minutes)
  • Medium (5-15 minutes)
  • Long (> 15 minutes)
Sort by: Newest
  • Newest
  • Oldest
  • A-Z
  • Z-A
EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control
Pulmonology
29 min
expert video

EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?
Rhinology
5 min
expert video

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?
Rhinology
5 min
expert video

What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?

How does a decrease in smell affect sleep disturbance? Is there any direct relation?
Rhinology
5 min
expert video

How does a decrease in smell affect sleep disturbance? Is there any direct relation?

How often do you suggest to assess sense of smell?
Rhinology
5 min
expert video

How often do you suggest to assess sense of smell?

When is the right time to consider a biologic in patients with CRSwNP?
Rhinology
5 min
expert video

When is the right time to consider a biologic in patients with CRSwNP?

What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or inflammation?
Rhinology
5 min
expert video

What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or inflammation?

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?
Rhinology
5 min
expert video

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?

What proportion of patients can achieve control in CRSwNP?
Rhinology
5 min
expert video

What proportion of patients can achieve control in CRSwNP?

Early Intervention and the Potential for Disease Modification in Children With AD
Dermatology
15 min
expert video

Early Intervention and the Potential for Disease Modification in Children With AD

Skin Barrier Dysfunction in AD
Dermatology
4 min
expert video

Skin Barrier Dysfunction in AD

Dysbiosis, Skin Infections, and Itch
Dermatology
3 min
expert video

Dysbiosis, Skin Infections, and Itch

    1
    ...
    192021
    ...
    29